Amgen Further Commits to U.S. Manufacturing with Ohio Investment
This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.
Biotechnology innovator, Amgen, has announced, in an April 25, 2025 press release, that it will be investing USD 900 million into expanding its Ohio manufacturing facility (1). With this latest financial announcement, the company will have invested a total of USD 1.4 billion into Central Ohio and created 750 U.S. jobs.
“Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. [This] investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines,” said Robert A. Bradway, Chairman and Chief Executive Officer at Amgen, in the press release (1). “Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”
The company first invested in Ohio in June 2021, when it revealed its plans to start construction on a state-of-the-art biomanufacturing facility (2). During this initial investment in the Columbus region, the company enhanced its manufacturing capabilities in the U.S. and created 400 jobs.
“Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth,” added Ohio Governor Mike DeWine, in the press release (1). “We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.”
In December 2024, the company also announced its planned manufacturing expansion in North Carolina in the U.S. (3). The planned USD 1 billion investment will be used to establish a second drug substance manufacturing facility in the state, which will incorporate cutting-edge technologies and sustainable practices.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Bradway in a company press release about the North Carolina investment (3). “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.”
“North Carolina's reputation as one of the world's leading centers for biotechnology soars even higher with today's decision by Amgen,” added North Carolina Governor Roy Cooper, in the press release (3). “North Carolina offers everything an innovative biotech company needs to succeed, especially our highly trained, dedicated and diverse workforce which is fine-tuned to the needs of this critical industry.”
Over the past few years, since 2017, Amgen has made approximately USD 5 billion worth of direct capital expenditures in the U.S. Through the investments into the U.S., Amgen is enhancing its global biomanufacturing network.
References
Amgen. Amgen Announces $900 Million Manufacturing Expansion, Creation of 350 New Jobs in Ohio. Press Release, April 25, 2025.
Amgen. Amgen Begins Construction on New Biomanufacturing Plant in Central Ohio. Press Release, Nov. 5, 2021.
Amgen. Amgen Announces $1 Billion Manufacturing Expansion in North Carolina. Press Release, Dec. 5, 2024.